Common challenges when seeking market access for rare disease therapies

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  Pic­tion Health, which start­ed as a mo­bile

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis